Zacks Investment Research on MSN1d
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Fierce Biotech2d
Vertex abandons islet cell-device combo after failing to improve diabetes biomarker
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
BioSpace2d
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
Business Wire5d
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
research-stage immunoprotective approaches - BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D ...
Vertex to Cease Clinical Trials on Diabetes Treatment
Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.
Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...